Skip to main content

Featured

Tariff Ultimatum on Iran Trade Sparks Global Tension

                                                Doing Business With Iran? Trump Says Pay a 25% US Tariff. A new 25% tariff threat from President Donald Trump has sent a jolt through international markets, after he declared that any nation continuing to trade with Iran would face steep U.S. penalties. The announcement, delivered abruptly through social media, signaled a sharp escalation in Washington’s effort to isolate Tehran economically. The move comes amid heightened criticism of Iran’s internal crackdown on dissent, which U.S. officials argue warrants stronger international pressure. By targeting not just Iran but its trading partners, the administration aims to force countries—including major global players—to reconsider their economic ties with Tehran. The threat immediately stirred uncertainty across global markets. Oil prices climbed...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment